How accurate are blood glucose meters?
If you have Type 1 or Type 2 diabetes, then you know how important it is to check your blood sugar, whether that’s with a CGM (continuous glucose meter) or the manual BGM (blood glucose meter). And when you are on one end of the spectrum, or just not convinced by your CGM number, you test with a blood glucose meter, right? But what if your BGM were inaccurate as well? Just how accurate is the quintessential diabetes management tool?
An independent study by the Diabetes Technology Society of 18 popular FDA-approved blood glucose monitoring systems released last month found that only six tested meters recorded BGLs as consistently and dependably as laboratory tests.
The six highest-functioning monitors reported results within 15 percent of laboratory tests taken for comparison 95 percent of the time. The other 12 meters were only on the mark between 71 and 92 percent of the time. While the deviation on the meters was sometimes minor, minor mistakes can eventually lead to big complications.
The study used BGMs bought in retail locations and tested 1,035 people in three different laboratory locations. It was conducted by a team of researchers led by David C. Klonoff, MD, of the Diabetes Research Institute at San Mateo, Calif.-based Mills-Peninsula Medical Center and funded by Abbott Laboratories.
The study was not isolated to people with T1D. Among those who participated in testing the BGMs, 370 people had T1D, while the others had T2D, pre-diabetes, or did not have diabetes at all.
The meters tested were developed by Bayer, Roche, Arkray, Agametrix, Abbott, LifeScan, Prodigy, Omnis Health, HDI/Nipro, BioSense Medical, Diabetic Supply of Suncoast and Philsys, and they represented 90 percent of the meters available on the market from 2013 to 2015.
The six meters that were consistently reported clinically accurate BGL results were the Bayer Contour Next, Roche, ACCU-CHK AVIVA Plus, Arkray Walmart ReliOn Confirm (Micro), Agamatrix, CVS Advanced, Abbott FreeStyle Lite, Roche Accu-Chek Smart View.
The study results come at a time when the FDA is continuing its crackdown on inaccurate BGMs. As monitors have become more of a staple in managing diabetes, companies have pushed hard to maximize on the product market. The thing to remember here is that not every meter that hits that market is trustworthy. The FDA approved 61 meters in 2012, while only approving 35 in 2015 and 20 in 2016.
While all the tested meters in the study were FDA-approved, it appears they were not all created equally. Data bias could account for the discrepancies in accuracy seen in the study. When the FDA reviews new meters for approval, it generally looks at company-reported trials and medical data. The study gathered independent meter data using a methodology that was more rigorous than the standards the FDA uses for approval.
The first step in protecting your health and safety may be seeing how your meter stacks up.
Passing Devices According to the Study
- Contour Next from Ascensia (formerly Bayer) – 100% accurate
- Accu-Chek Aviva Plus from Roche – 98% accurate
- Walmart ReliOn Confirm (Micro) from Arkray – 97% accurate
- CVS Advanced from Agamatrix – 97% accurate
- FreeStyle from Abbott – 96% accurate
- Accu-Chek SmartView from Roche – 95% accurate
Failing Devices According to the Study
- Walmart ReliOn Prime from Arkray – 92% accurate
- OneTouch Veriofrom LifeScan – 92% accurate
- Prodigy Auto Codefrom Prodigy – 90% accurate
- OneTouch Ultra 2from LifeScan – 90% accurate
- Walmart ReliOn Ultima from Abbott – 89% accurate
- Contour Classicfrom Bayer – 89% accurate
- Embracefrom Omnis Health – 88% accurate
- True Resultfrom HDI/Nipro (Trividia) – 88% accurate
- True Trackfrom HDI/Nipro (Trividia) – 81% accurate
- Solus V2 from BioSense Medical – 76% accurate
- Advocate Redi-Code+ from Diabetic Supply of Suncoast – 76% accurate
- Gmate Smartfrom Philosys – 71% accurate
Researchers involved in the study said the findings could be especially important to Medicare patients. U.S. Department of Health and Human Services data shows that meters that failed the study standards accounted for 68 percent of the BGMs mail-ordered through Medicare in 2016.
Full data and methodology on the study can be seen here.